Receptor News and Research

RSS

Profilin-1 gene influences survival time in Lou Gehrig's disease

A team of scientists, including faculty at the University of Massachusetts Medical School (UMMS), have discovered a gene that influences survival time in amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease).

27 Aug 2012

$LCZ696 demonstrates beneficial effects in heart failure patients with preserved ejection fraction$

LCZ696 demonstrates beneficial effects in heart failure patients with preserved ejection fraction

The novel angiotensin receptor neprilysin inhibitor, LCZ696, demonstrated beneficial effects in heart failure patients with preserved ejection fraction (HFpEF), according to results of the PARAMOUNT (Prospective compArison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion) trial.

27 Aug 2012

Prasugrel as safe as clopidogrel in preventing heart attack, stroke and death

The first trial to study patients with acute coronary syndrome who do not undergo coronary stenting or bypass surgery found no significant difference between two anti-clotting drugs - prasugrel and clopidogrel - in preventing the first occurrence of death, heart attack or stroke, according to Duke University Medical Center cardiologists.

27 Aug 2012

New molecular mechanism plays a crucial role in inhibiting TGF-beta signaling

Researchers headed by Maria Macias an ICREA researcher at the Institute for Research in Biomedicine (IRB Barcelona) and Joan Massagu-, a Howard Hughes Medical Institute investigator at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York, have identified a new molecular mechanism that plays a crucial role in the control of the activation of certain genes associated with cancer.

27 Aug 2012

MRC awards grant to design new drug for treatment of chronic pain

Scientists at the University of Liverpool and the Royal Liverpool University Hospital have been awarded -1.4 million to design a new drug for the treatment of chronic pain.

24 Aug 2012

Vandetanib shows efficacy in thyroid cancer

The tyrosine kinase inhibitor vandetanib could significantly extend progression-free survival in patients with locally advanced or metastatic differentiated radioiodine-refractory thyroid cancer, show results of a small phase II randomized trial.

24 Aug 2012

LXRbeta may play a role in prevention and treatment of Parkinson's

Scientists at the University of Houston (UH) have discovered what may possibly be a key ingredient in the fight against Parkinson's disease.

24 Aug 2012

Results from Biodesix VeriStrat phase II advanced lung cancer trials

Biodesix today announced that VeriStrat results from two phase II advanced lung cancer trials will be presented at the upcoming 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.

24 Aug 2012

Women with heart attack symptoms receive lower quality of care than men

A new study published recently in the American Journal of Medicine, conducted by researchers in the Cardiac and Vascular Institute at NYU Langone Medical Center, found there was significantly lower quality of care and worse outcomes in women compared to men - particularly young women under age 35 who had heart attack symptoms.

23 Aug 2012

TREM-1 gene disrupts inflammatory process implicated in liver cancer

Researchers at the Georgia Health Sciences University Cancer Center have identified a gene that disrupts the inflammatory process implicated in liver cancer.

23 Aug 2012

NIAID announces 14 grants for basic research to identify new HIV vaccine approaches

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded 14 grants totaling $7.8 million in first-year funding for basic research to identify new approaches for designing a safe and effective HIV vaccine.

22 Aug 2012

Research explores impact of radiotherapy in older women with low risk of breast cancer recurrence

A Rhode Island Hospital radiation oncologist says in a new editorial that research exploring the impact of radiotherapy in older women with low risk of breast cancer recurrence has little effect on actual clinical decisions.

22 Aug 2012

New tool reveals surprising clues about how cancer cells respond to therapy

A new tool to observe cell behavior has revealed surprising clues about how cancer cells respond to therapy, and may offer a way to further refine personalized cancer treatments.

21 Aug 2012

Methyl-glyoxal could play a major role in abdominal obesity, insulin resistance and type 2 diabetes

Researchers at Mount Sinai School of Medicine have identified a common compound in the modern diet that could play a major role in the development of abdominal obesity, insulin resistance, and type 2 diabetes.

21 Aug 2012

Study identifies mode of death of cone photoreceptor cells in animal model of RP

Research conducted at the Angiogenesis Laboratory at Massachusetts Eye and Ear Infirmary, has for the first time, identified the mode of death of cone photoreceptor cells in an animal model of retinitis pigmentosa (RP).

21 Aug 2012

Enzalutamide extends castration-resistant prostate cancer survival

Enzalutamide treatment significantly improves survival in men with castration-resistant prostate cancer, demonstrate phase III trial results published in TheNew England Journal of Medicine.

20 Aug 2012

Pyruvate kinase M2 fuels tumor growth by influencing H3 histone protein

A metabolic protein that nourishes cancer cells also activates tumor-promoting genes by loosening part of the packaging that entwines DNA to make up chromosomes, a team led by scientists at The University of Texas MD Anderson Cancer Center reports in the Aug. 16 issue of Cell.

17 Aug 2012